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Abstract Thyrotropin or thyroid-stimulating hormone
(TSH) is used as a marker for thyroid function. More pre-
cise and more sensitive immunoassays are needed to facil-
itate continuous monitoring of thyroid dysfunctions and to
assess the efficacy of the selected therapy and dosage of
medication. Moreover, most thyroid diseases are autoim-
mune diseases making TSH assays very prone to immuno-
assay interferences due to autoantibodies in the sample ma-
trix. We have developed a super-sensitive TSH immunoas-
say utilizing nanoparticle labels with a detection limit of 60
nU L−1 in preprocessed serum samples by reducing nonspe-
cific binding. The developed preprocessing step by affinity
purification removed interfering compounds and improved
the recovery of spiked TSH from serum. The sensitivity
enhancement was achieved by stabilization of the protein
corona of the nanoparticle bioconjugates and a spot-coated
configuration of the active solid-phase that reduced sedi-
mentation of the nanoparticle bioconjugates and their con-
tact time with antibody-coated solid phase, thus making use
of the higher association rate of specific binding due to high
avidity nanoparticle bioconjugates.
Keywords Sandwich-type immunoassay . Time-resolved
fluoroimmunoassay . Nanoparticle bioconjugate .
Immunoassay interference . Nanoparticle protein corona
Abbreviations
HAB Human autoantibody
HAMA Human anti-mouse antibody
LLD Lowest limit of detection
TSH Thyroid-stimulating hormone
Introduction
Eu-doped nanoparticles can be manufactured to afford high
colloidal stability; good protection of Eu-chelates from sol-
vent; very low self-quenching owing to long Stoke’s shift of
the Eu-chelates; density that is close to water’s density to
reduce sedimentation; and a dense coating of carboxyl groups
on their surface for efficient bioconjugation [1]. Most impor-
tantly the Eu-doped nanoparticles facilitate sensitive time-
resolved low background detection of Eu-emission and are
thus perfect label candidates for assays that require high sen-
sitivity. However, while the nanoparticle-based assay concepts
have high signal output, their applicability has been limited
because of assay matrix-related interference and relatively
high level of nonspecific binding observed in the assays
[1–3]. Matrix effects in an immunoassay usually refer to in-
terference arising from the sample matrix (e.g., whole blood,
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serum, or saliva) that contains the analyte. Previously, we have
used a systematic approach to characterize different aspects of
a sandwich-type non-competitive immunoassay utilizing
nanoparticle bioconjugates as labels [4]. We have developed
a rational basis for development of immunoassays using nano-
particles as labels [5–7] and now expand this work to describe
assay matrix-derived interactions [8].
Matrix-related interferences like high nonspecific binding
and cross-reactivity of antibodies, autoantibodies (HAB), hu-
man anti-mouse antibodies (HAMA), and polyanions
(heparin) often hamper precise measurements in clinical sam-
ples, e.g., in serum [9, 10]. In most assays, serum samples are
preprocessed from whole blood by removing the blood cells
and clotting factors, but they still contain a variety of factors
that prevent reaching the lowest limit of detection (LLD) that
can be obtained with artificial buffer samples. Binding of a
nanoparticle bioconjugate is defined by nanoparticle material
and the bioconjugate layer, but also by their biomolecule co-
rona [11]. The biomolecule corona of a nanoparticle describes
a loosely bound dynamic layer of non-covalently associated
proteins and other biomolecules that in part mediate nanopar-
ticle interactions [12]. TSH and thyroid hormone assays are
especially prone to HAB interference, as both Graves’ and
Hashimoto’s diseases are autoimmune disorders, implying
the prevalence of autoantibodies to the hormones or their re-
spective receptors. Thus, optimization of TSH assay condi-
tions is of particular interest. There are a number of sample
preprocessing strategies for various immunoassays, but none
that would directly focus on removing nanoparticle corona-
forming proteins.
We used TSH as a model analyte to demonstrate advances
in immunoassay technology. TSH is a 28-kDa glycoprotein
hormone secreted by the pituitary gland. TSH comprises two
chemically different subunits, α and β, which are joined by
non-covalent bonds. The normal range of TSH in serum is
0.3–5.0 mU L−1 (0.05–0.8 μg L−1), but over 95% of screened
normal euthyroid volunteers have TSH levels below
2.5 mUL−1 [13]. Abnormal TSH level can be a sign of thyroid
malfunction, and it can be used as a tool to diagnose thyroid
diseases and to monitor the effectiveness of therapy. Patients
suffering from hypothyroidism have elevated TSH level, and
more precise TSH assays allow one to distinguish subclasses
of hyperthyroidisms. Over 13 million Americans are believed
to be affected by some type of thyroid disease, but thyroid
diseases nevertheless remain underdiagnosed because of inef-
fective screening programs [14]. Furthermore, precise analysis
of thyroid function is required during pregnancy, as one to
three in 200 pregnancies are affected by thyroid dysfunction
caused by the autoimmune disorders Graves’ and
Hashimoto’s diseases [15, 16]. These conditions are danger-
ous and may cause congestive heart failure for the mother,
miscarriage, and attention deficit hyperactivity disorder symp-
toms or impaired cognitive development for the child. The
likelihood of adverse effects is increased especially if the thy-
roid disease develops during the first trimester [16, 17].
Furthermore, there is increasing evidence on thyroid dysfunc-
tion being one of the factors triggering or aggravating meta-
bolic syndrome [18, 19]. Slightly elevated TSH levels have
been linked to metabolic syndrome, also in euthyroidism; in
particular, young females with a TSH in the upper normal
range (2.5–4.5 mU L−1) were more likely to be obese, had
higher triglyceride levels, and were more likely to be affected
by metabolic syndrome.
Good precision and accuracy are often problematic to
achieve at the same time, and therefore small changes in trends
cannot usually be detected in a number of diagnostic test for-
mats. Hence, more powerful tools are required to quantitative-
ly detect low concentrations of target analyte, small changes in
concentrations, and trend reversals due to intervention therapy
[19]. In plasma and serum the matrix-related interferences
often hamper precise measurements, especially in the case of
autoimmune disorders [20]. In this study we demonstrate the
effects of our conceptual findings on the TSH immunoassay
performance, and especially their potential to reduce matrix
interference. Our optimized europium(III) nanoparticle label-
ing technology in sandwich-type immunoassays is shown to
improve the LLD to 60 nU L−1, which equals 450 amol L−1
[21], and is 1/50 of the LLD obtainable by the current market
leaders in TSH assays. The assay is based on 96 well-plate
format, where Eu(III)-labeled nanoparticles are used as labels
and time-resolved fluorescence is used to monitor TSH quan-




modified, monodisperse, polystyrene nanoparticles with a
92-nm diameter were acquired from Seradyn (Indianapolis,
IN). The fluorescent properties of these particles were de-
scribed previously [22, 23]. The particles are stabile in aque-
ous suspensions and nanoparticle material protects doped
Eu-chelates, thereby facilitating stabile fluorescence [24].
Anti-TSH monoclonal antibodies (clones anti-TSH 5404
SP-1 and anti-TSH 5409 SPTNE-5) were purchased from
Medix Biochemica (Kauniainen, Finland). Antibody frag-
ments (anti-prostate specific antigen (PSA) Fab 5A10, Fab
anti-TSH 5409, and anti-TSH 5404) were produced at the
Department of Biotechnology in the University of Turku
[25, 26]. Affinity constants for the antibodies were 9.3 ×
108 L mol−1 and 2.2 × 1010 L mol−1 for anti-TSH 5409 and
anti-TSH 5404, respectively [27]. KaivogenSA96™
streptavidin-coated microtitration low-fluor plates, KVG
buffer [50 mmol L−1 Tris–HCl (pH 7.8), 150 mmol L−1
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NaCl, 7.7 mmol L−1 NaN3, 76 μmol L
−1 bovine serum albu-
min, 80 μmol L−1 Tween 40, 3 μmol L−1 bovine γ-globulin,
20 μmol L−1 diethylenetriaminopentaacetic acid] and wash-
ing solution (5 mmol L−1 Tris–HCl, pH 7.8 containing
150 mmol L−1 NaCl, 3.5 mmol L−1 Germall II, and
40 μmol L−1 Tween 20) were from Kaivogen Oy (Turku,
Finland). N-Hydroxysulfosuccinimide (NHS) was acquired
from Fluka (Buchs, Switzerland); bovine serum albumin
fraction V (BSA), biotin, and N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide (EDC) were purchased from Sigma
(Steinheim, Germany).
Conjugations and coatings
Nanoparticles were covalently coated with Mab anti-TSH
5404 according to a previously described procedure using
6 μmol L−1 Mab [22] (Fig. 1). The monoclonal antibodies
were biotinylated randomly through lysines according to a
protocol described earlier [26]. The Fab fragments were pro-
duced, site-specifically biotinylated, and coated on
streptavidin-functionalized solid phase according to a previ-
ously described procedure [5]. The nanoparticle bioconjugates
were diluted 5- to 1000-fold into KVG buffer or a subset of the
buffer’s components and incubated for at least 24 h to allow
their protein corona to re-equilibrate [8].
The spot-wells were produced by washing streptavidin-
coated microtitration wells twice with the washing solution
to remove preservatives and loosely bound proteins. To pro-
duce fully coated wells 3 × 10−13 mol of biotinylated Fab frag-
ments were incubated in the prewashed wells in 30 μl of KVG
buffer for 20 min. In spot-coating 1 × 10−13 mol of biotinylat-
ed Fab fragment was incubated in 1 μL of KVG buffer for
10 min. The spot was produced by pipetting a drop of capture
antibody solution halfway between the edge and center of the
well of a streptavidin-functionalized 96-well plate. The major-
ity of the solid phase is thus left devoid of the capture anti-
body, and binding of the nanoparticle bioconjugate on it will
thus be significantly lower (Fig. 1b) [8].
Immunoassays
Known concentration of TSH was spiked in KVG buffer and
incubated for 20 min. Alternatively, the TSH was mixed into
affinity purified serum/KVG buffer mixture and incubated for
10–20 min (Fig. 1). In the one-wash assay configuration TSH
was spiked into a 1:1 mixture of affinity-purified pooled se-
rum and KVG buffer, and 20 μL of this mixture was then
transferred to a reactionwell. After 10min of incubation under
fast circular shaking (DELFIA Plateshake 1296-003, with a
circular vibrating motion, PerkinElmer), 3 × 107 detector
nanoparticle bioconjugates in 30 μL of KVG buffer were
added to the reaction wells and incubated for another 30 min
under fast circular shaking. Subsequently, the wells were
washed six times and aspirated. The time-resolved fluores-
cence from the nanoparticle–antibody bioconjugates was
measured by excitation at 340 nm and detection at 615 nm
using time-resolved fluorescence of plate reader Victor2 1420
Multilabel counter (Wallac, PerkinElmer) [8].
Affinity purification
Serum was isolated from peripheral blood of healthy volun-
teers (N = 7; 3 male, 4 female) who gave their informed writ-
ten consent. Affinity purification was performed by incubat-
ing pooled human serum inmicrotiter wells coated with 50μL
of 100 nmol L−1 anti-TSH Mab 5404 (Fig. 1b). Alternatively,
the serum was purified with an antibody against prostate spe-
cific antigen (PSA) anti-PSA Fab 5A10 (50 μL of
200 nmol L−1) that was, apart from the paratope, structurally
similar to the anti-TSH antibodies (Fig. 1c). In this experiment
a female donor’s serum was used because of lack of PSA in
the circulation. The donors’ (N = 2) TSH was tested to be
below 1 mU L−1 2–4 weeks before the serum sample for this
study was taken. The incubation lasted 15 min, and the serum
was treated twice in a volume of 60 μL. The purified serum
was extracted from wells and stored refrigerated or frozen
until used. We used regular two-way ANOVA with Sidak’s
test for multiple comparisons available in GaphPad Prism to
test significance of the observed difference between affinity-
purified samples and untreated samples.
Dynamic light scattering measurements
The nanoparticle bioconjugates were vortexed, diluted into
KVG buffer, sonicated, vortexed again, after which the dy-
namic light scattering (DLS) was measured immediately
(Zetasizer Nano, Malvern Instruments, Worcestershire, UK).
The stabilized samples were diluted, sonicated, vortexed, and
allowed to re-equilibrate their protein corona for 24 h, after
which the samples were sonicated and vortexed again and
DLS was measured.
Results
Stabilization of protein corona on nanoparticle
bioconjugates
The colloidal stability of nanoparticle bioconjugates in sus-
pension is determined by their surface potential [28], stability
of conjugated antibodies [29], ionic strength and pH of the
assay buffer [30], concentration of nanoparticle bioconjugates
in the suspension, detergents in the assay buffer, presence of
blocking proteins, and stability of their protein corona [12]. In
contrast to small molecular labels attached to antibodies that
have a miniscule influence on their microenvironment, the
Super-sensitive fluoroimmunoassay for TSH
nanoparticles form a polarized solvation shell near the surface
of the particle where exchange of molecules will be slower
[8]. As the nanoparticle bioconjugates are typically diluted in
the assay buffer from a separate storage buffer, i.e., stock
suspension, the equilibrium of proteins loosely adhered to
their surface is perturbed. During formation of the new
Fig. 1 Schema and flow diagram of the assay concept. a Sandwich
complex. Carboxyl groups on Eu-doped polystyrene nanoparticles are
functionalized with EDC-NHS (treatment to generate succinimidyl
groups). Then the particles are coated with monoclonal anti-TSH anti-
bodies to form the nanoparticle bioconjugates and unreacted succinimidyl
groups are converted back to carboxylic acid through hydrolysis. The
solid phase is first coated with streptavidin and blocked with BSA; sub-
sequently, an area of approximately 1 mm2 is functionalized with anti-
TSH Fab fragments recognizing a different epitope in TSH than the
nanoparticle-conjugated antibodies. b To optimize the assay we needed
TSH-free human serum and we produced it by affinity purification of
pooled human serum. For the purification we used 2 × 10 min incubation
of the serum in anti-TSH-coated microtiter wells, after which we spiked
samples with known concentrations of recombinant human TSH. The
TSH was added to serum into equal volume of KVG buffer, and 20 μL
of this mixture was added to spot-coated wells. After 10 min incubation
with fast circular mixing the nanoparticle bioconjugates were added in a
volume of 30μL and incubation was continued for 30min. Subsequently,
unbound nanoparticle bioconjugates were washed away, and wells were
read for time-resolved Eu-fluorescence. c To reduce nonspecific binding
in a nanoparticle-based immunoassay we used a nonspecific affinity pu-
rification step to remove compounds interfering with the assay. First, a
sample of female serum low–normal range TSH sample was spiked with
100 μU L−1 of TSH in KVG buffer (Fig. 4) and incubated for 2 × 10 min
in anti-PSA Fab-coated wells (women do not have PSA in circulation so
nothing specific is removed). A replicate sample was spiked, but left
untreated. 20 μL of both samples were transferred to spot-coated wells
and assayed like in protocol b. Difference in TSH-assay performance is
presented in Fig. 4
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equilibrium and molecule exchange on the nanoparticle sur-
face, low energy bonds (e.g., electrostatic and van der
Waals) form and break, and this may generate unwanted
nonspecific interactions [31–33]. We discovered that stor-
ing nanoparticle bioconjugates in KVG buffer (a buffer with
blocking proteins and detergent) at a concentration of no
higher than 100 times that of the final usage concentration
in the following assay increased the signal-to-noise ratio of
the assay by nearly threefold (Fig. 2a). This can be explained
by agglomeration of nanoparticle bioconjugates upon com-
ing into contact with the high protein concentration in the
serum matrix [34] or the assay buffer, as they are diluted
from a high storage concentration.We examined the process
by dynamic light scattering (DLS) experiments where nano-
particle bioconjugates were diluted in KVG buffer and mea-
sured immediately or after 24 h protein corona stabilization.
We observed an increase of hydrodynamic radius of single
particles corresponding to the adsorption of matrix proteins
onto the nanoparticle bioconjugates and formation of a new
protein corona (Fig. 2b). Furthermore, we observed both
fewer and smaller aggregates in the stabilized samples
(Fig. 2c). The aggregates represented a particle volume be-
low 5% of the total DLS signal; hence, these aggregates
were difficult to measure, resulting in high variation of sig-
nal between the replicate samples. The controlled reforma-
tion of the protein corona (Fig. 2b) appears to reduce
agglomeration-inducing interactions between particles
(Fig. 2c), and as a result the immunoassay had higher spe-
cific signal, as more binders were available, and lower non-
specific signal (Fig. 2a), as prevalence of large aggregates
prone to sediment is reduced.
Components in the protein corona may improve colloidal
stability and increase the activity of the nanoparticle biocon-
jugates by reducing unwanted interactions or decrease their
Fig. 2 Concentration-dependent protein corona stabilization. a The
nanoparticle bioconjugates were stored in KVG buffer at various
concentrations and then used to perform a one-step assay for 100 μU
L−1 TSH in KVG buffer assay matrix. Dilution to the assay concentration
(2.5 × 106 particles μL−1) was made in a single step. Stabilization of the
particle suspension was achieved up to a concentration 100-fold higher
than the concentration used in the assay. Mean values of three replicates
are presented as bars and standard deviation as error bars. bMain peak of
a DLS measurement of nanoparticle bioconjugates diluted into KVG
buffer measured immediately after dilution, sonication, and vortexing
(black circles, black line represents a mean of 3 replicates) and one mea-
sured after dilution, 24 h stabilization, sonication, and vortexing (red
squares, deep red line represents a mean of 3 replicates). c
Representation of the aggregate peak of the same DLS measurement;
while we observed aggregates only in some of the samples, typically
the aggregates were fewer and smaller in the stabilized samples. A zero
value indicates that the amount of aggregates in the sample fell below the
detection limit
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binding activity by masking binding sites [32]. To investigate
the stabilization effect in more detail we did a component-by-
component test of the KVG buffer ingredients to discover the
components responsible for the effect. Also, we wanted to re-
veal whether the effect was due to more dispersed particle sus-
pension after the dilution rather than due to any specific buffer
components. The test of the buffer ingredients was performed at
a particle concentration of 1.25 × 108 particles μL−1 (Fig. 3) [8]
. The most critical storage buffer component regarding the sta-
bilization was the blocking protein BSA, and the second most
important was detergent Tween 40. The importance of the de-
tergent was less pronounced when buffer pH and salinity, i.e.,
ionic strength, were adjusted to physiological range.
Stabilization using the optimum pH, physiological ionic
strength, blocking protein, and detergent in the diluted particle
suspension resulted into a nearly threefold improvement in
signal-to-background ratio. However, when these components
were added to the storage buffer at a particle concentration
1.25 × 1010 particles μL−1, no benefit was observed. This
would indicate that the stabilization effect is dependent on the
surface kinetics, as increasing the concentration of stabilizing
agents to match the surface area did not provide a similar result.
Control of association time by solid-phase organization
We have shown with force spectroscopy and surface plas-
mon resonance that the association rate of specific binding
of nanoparticle bioconjugates (kon) is up to 200,000-fold
higher than kon for nonspecific binding, while koff for both
specific and nonspecific binding was too slow to be mea-
sured [7]. Also, nonspecific binding occurs mainly between
two antibody-coated surfaces [5] and is dependent on the
density and stability of the antibodies [6]. We were able to
show that colloidal stability is critical for assay performance
(Fig. 2); to further reduce sedimentation and nonspecific
binding, we decided to reduce the binding time of the nano-
particle bioconjugates with fast liquid flow induced by
mixing and a small area for specific binding (Figs. 1 and
4) [35, 36]. The small area of the active solid phase was
produced by adding the Fab capture antibody in a 1-μL drop
on a well of a streptavidin-functionalized 96-well plate,
halfway between the edge and center of the well. At this
location the liquid flow induced by circular shaking was
the fastest and no edge effect could be expected. Thus, the
majority of the solid phase was left devoid of the capture
antibody. Binding of the nanoparticle bioconjugate towards
the streptavidin-coated and BSA-blocked surface was 10–
500 times less efficient than to antibody-coated surface [5,
23]; hence, a lower level of background signal was observed
with zero TSH calibrator samples. The spot-coated wells
provided 3- to 10-fold higher signal-to-background ratio
than the fully coated wells (Fig. 4). Moreover, the assays
in spot-coated wells required lower concentration nanopar-
ticles to produce optimal signal level (see Electronic
Supplementary Material (ESM) Fig. S1), because we direct-
ed the excitation beam of the Victor2-multilabel counter to
the coated spot and achieved a strong excitation of the spe-
cifically bound nanoparticle bioconjugates. The nonspecific
Fig. 3 Component-by-
component investigation of the
storage buffer composition at
concentration of 1.25 × 108
particles μL−1 and 1 mU L−1 of
TSH. Mean values of three
replicates are presented as bars
and standard deviation as error
bars. Impact of the storage buffer
composition is measured by
testing the assay performance
(signal-to-background ratio) with
the particles stored in the
specified buffer and then diluted
into KVG buffer. The best signal-
to-background ratio was obtained
with particles stored in
50 mmol L−1 Tris–HCl (pH 7.8),
150 mmol L−1 NaCl, 76μmol L−1
bovine serum albumin, and
80 μmol L−1 Tween 40
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signal is directly proportional to the number of nanoparticle
bioconjugates used in the assay, so this in part helped to
reduce the background signal [4].
Sample preprocessing by affinity purification
The normal range of TSH in patient samples is approximately
0.4–2.5 mU L−1. To measure a TSH calibration curve, the
serum samples were prepared from pooled serum samples
by affinity purification with anti-TSH antibodies, and subse-
quently these samples were spiked with recombinant TSH
(Fig. 1b). We observed that the Eu-signal measured from zero
TSH calibrator of TSH-stripped serum samples was lower
than that measured from buffer-only samples (Fig. 4).
Analyzing these samples we observed a reduced and repro-
ducible level of nonspecific background signal in the zero
TSH calibrator sample (Fig. 4). This implies that the protocol
used to remove TSH from the pooled serum also removed
other cross-reactive or interfering compounds from the sam-
ple. Removal of such compounds from a clinical sample
would naturally enable detection of even lower concentrations
of TSH.We then asked if it would be possible to remove these
interfering compounds with a pretreatment using an antibody
that does not recognize anything specific in the serum sam-
ples. To quantify this observation, we utilized anti-PSA 5A10
Fab fragment [5]-coated wells to purify pooled female serum
samples with low-normal range TSH (0.4–1 mU L−1) after
they had been spiked with (100 μU L−1) recombinant TSH
(Fig. 1c). The anti-PSA Fab was produced in a similar manner
as the anti-TSH Fab fragment, and the amino acid sequence
was over 90% similar. However, in female serum samples
there should not exist any epitopes that the anti-PSA Fab
fragment would recognize, and therefore the observed affinity
purification was not caused by removal of any specific
interacting compound. After the purification step, we mea-
sured recovery of spiked recombinant TSH 100 μU L−1 in
samples with 50%, 20%, 10%, and 5% of serum (Fig. 5).
The TSH concentration of all the samples was equal, and only
the amount of serum differed. Therefore, with perfect recovery
of recombinant TSH, the signal in all measurements should be
equal to 5% sample. The observed decrease of Eu-signal rep-
resents reduced TSH recovery due to matrix-related effects.
We observed that at serum quantity over 5% (v/v) the affinity
purification produced a significant increase of TSH recovery
(Fig. 5). The effect of affinity purification was stronger the
higher the proportional amount of serum in the sample was.
Super-sensitive TSH assay utilizing nanoparticle
bioconjugates
We used our findings to develop a heterogeneous sandwich-
type immunoassay utilizing nanoparticle bioconjugates to
measure TSH in affinity-purified pooled human serum. A
standard curve measured using three replicates of each cali-
brator reached an LLD of 60 nU L−1 (Fig. 6); this corresponds
to 450 amol L−1 or 10,000 molecules in a sample volume of
Fig. 5 Affinity purification increases the sensitivity of the assay. We
added (100 μU L−1) of TSH (Sample + 100 μU L−1) into female serum
samples with low–normal range TSH (Sample) (approximately 0.4–
1 mU L−1). TSH recovery was illustrated by plotting Eu-signal
(Sample + 100 μU L−1) – Eu-signal (Sample). The serum samples were
not purified (black) or affinity purified (gray) with Fab 5A10 anti-PSA
antibodies that beared a resemblance to anti-TSH antibodies, but having
no specific antigens in the serum. Addition was done in respect to total
well volume, and thus all samples should have given the same Eu-signal.
Differences between treated and untreated samples were tested with reg-
ular two-way ANOVAwith Sidak’s test for multiple comparisons; ns p >
0.05, **p < 0.01, and ***p < 0.001
Fig. 4 Comparison of TSH assay signal-to-background ratios in KVG
buffer (buffer, gray bars) and in 50% affinity-purified serum (serum,
black bars). TSH concentration was 100 μU L−1; mean values of three
replicates are presented as bars and standard deviation as error bars. The
assay utilized normal (ctrl-NP) and protein corona-stabilized nanoparticle
bioconjugates (s-NP) and fully coated (FC) and spot-coated (spot) micro-
titer wells. The optimized configuration gave 10-fold higher signal-to-
background ratio in KVG buffer configuration with fully coated well
and control NPs and a 100-fold higher ratio in 50% affinity-purified
serum configuration with fully coated well and control NPs
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20 μL. The LLD was defined as the signal of 3 × SD of the
zero calibrator over the signal obtained from zero calibrator.
Furthermore, in the presented assay the slope of signal in-
crease for each 1 μU of TSH in serum was 13,500 Eu-signal
units. The high sensitivity (signal increase per unit of TSH) of
the assay enabled high precision in the determination of a
patient’s TSH level.
The assay is a one-wash configuration where the undiluted
sample is first dispensed into a microtiter well and thereafter
tracer nanoparticles are added to the same well without a sep-
aration step in between. A single washing step is required
before the time-resolved luminescence signal is recorded.
The presented assay is relatively easy to perform, total time
to conduct the assay is 40 min, and it requires low amounts of
sample and reagents, although the affinity purification in-
creases slightly with the amount of antibodies used. We were
able to operate the assay with serum volumes of 5–40 μL.
Further reduction of sample volume induced a non-linear re-
duction in measured LLD. There was no kinetic requirement
for the incubation period, but we chose to measure the signal
when equilibrium was reached for the binding reaction be-
cause we wanted the principles presented to be more univer-
sally applicable.
Discussion
Our longstanding aim has been to establish general princi-
ples for developing sandwich-type immunoassays utilizing
Eu-nanoparticle labels [4–8, 23]. Here we applied those
principles, focusing on the matrix-related nonspecific bind-
ing and developed a sandwich-type heterogenic immunoas-
say for TSH that has a lower LLD and higher sensitivity
than previously presented assays. The LLD of 60 nU L−1
in our assay is nearly 1/50 of that of the market-leading
assay systems: the chemiluminescence microparticle im-
munoassay (CMIA) 2.5 μU L−1 by Architect i2000 SR
(Abbott Diagnostics) or the electrochemiluminescence im-
munoassay (eCLIA) 5 μU L−1 by Cobas 6000 (Roche
Diagnostics). Furthermore, we introduce a concept of sta-
bilization of the protein corona surrounding the nanoparti-
cle bioconjugates that reduced nonspecific binding, espe-
cially in clinically relevant matrixes. The presented assay
concept will facilitate better recovery of TSH from serum
and more precise TSH measurements, and thereby smaller
sample volumes. The observed increase in recovery sug-
gests that there are components preventing interaction of
nanopart icle label and TSH in the serum matrix.
Furthermore, the observed decrease of background signal
after the antibody capture-based removal of TSH implies
that some of these interacting components cause the in-
crease of nonspecific binding. Although we have not de-
fined the interacting compounds, we suggest that a prepro-
cessing step comprising an affinity purification with an an-
tibody not binding the analyte or matrix filtration (Fig. 5)
would increase the performance of many clinical immuno-
assays and would help to remove both false positives and
negatives [20, 37, 38]. We hypothesize that removal of in-
terfering compounds would be especially important in sam-
ples where HABs are likely to be present [15]. Furthermore,
we propose that the best result of affinity purification is
likely to be produced by an antibody resembling the capture
antibody that has structural differences only in the hyper-
variable loops of the paratope.
The assay performance was further improved with of spot-
coated configuration of the active solid phase and stabilized
protein corona surrounding the nanoparticle bioconjugates.
Dilution of the nanoparticle bioconjugates into another buffer
or assay matrix causes a change in their protein corona, i.e.,
proteins loosely adhering to the nanoparticles [12, 33]. Rapid
change in the protein corona may cause aggregation of the
nanoparticles, as macromolecules in the matrix transiently in-
teract with multiple nanoparticles. These interactions may also
mask some of the binding sites, if a dense corona is electro-
statically attracted to surround a nanoparticle (Figs. 2 and 3)
[8]. These effects can be avoided by incremental dilution of
nanoparticles and maintaining adequate concentration of sta-
bilizing compounds (Fig. 3) and allowing time for the protein
corona to stabilize before the assay in conducted (Fig. 2).
Moreover, we provide evidence that the stabilization effect is
independent on nanoparticle concentration and that re-
formation of the protein corona can be observed with DLS
(Fig. 2). The benefit of spot-coated solid-phase configuration
(Figs. 4 and 6) is likely to originate from reduced rolling of
nanoparticles on an antibody-coated surface [6] that would
potentially increase nonspecific binding by allowing more
time for the nanoparticle bioconjugates to adhere via
Fig. 6 TSH standard curve measured in spiked affinity-purified serum
samples by using three replicates of each calibrator. The LLD of the assay
was 60 nU L−1 corresponding to 450 aM or 10,000 molecules in sample
volume of 20 μL. Background signal was subtracted from the data points
presented and the average background signal is set to zero value and LLD
at 3 × SD of background
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nonspecific bonds. Also, the configuration concentrates the
analyte in a confined area promoting efficient multivalent rec-
ognition by the nanoparticle. Yet another mechanism through
which an improved signal-to-background ratio could be me-
diated is the decrease in the optimal amount of nanoparticle
bioconjugates needed for the assays done in spot-coated wells
(see ESM Fig. S1). Our assay concept, however, could not be
applied to heparin plasma, most likely because of interactions
caused by the polyanions. The ability to perform a washing-
free immunoassay in a whole blood sample smaller than
20 μL can be seen as a prerequisite for patient self-testing
and point-of-care systems testing for biomarkers in the circu-
lation [39]. While we present a heterogeneous test, the LLD
measured is sufficient to design a separation-free or homoge-
nous system that typically performs at an order of magnitude
higher LLD or better. We suggest that the principles found in
this study are applicable to, e.g., lateral flow-based systems.
The higher the sensitivity of the assay is, the smaller the
concentration differences that can be measured. Such a prop-
erty is of importance when assessing drug response and ap-
propriate dosage, especially in rapidly developing conditions
like pregnancy-related thyroid dysfunctions where both too
high and too low thyroid hormone concentrations pose a risk
for the fetus and the mother [16, 17, 40]. These conditions
require exact and repeated measurements to adjust the drug
dosage over the course of pregnancy [41], and in some cases
treatment needs to be started to promote fertility [40].
Furthermore, thyroid hormones modulate many metabolic
pathways relevant to the resting energy expenditure, and hy-
pothyroidism is associated with weight gain and metabolic
syndrome [42]. Recognizing trend reversals is essential in
the treatment of metabolic syndrome [19, 43].
Conclusions
A super-sensitive time-resolved fluoroimmunoassay for TSH,
LLD 60 nU L−1, utilizing europium(III) nanoparticle labels
with reduced nonspecific binding was developed. An affinity
purification step with an antibody bearing close resemblance
to the detecting and capture antibody removed interfering
compounds from the sample matrix [8]. Combining these
properties with previously found general parameters in sand-
wich immunoassays [5–7] facilitated detection of TSH con-
centrations that were 1/50 of LLD of the current market-
leading technologies (Fig. 6) and increased sensitivity [21].
With more accurate diagnostics, intervention therapy can start
earlier, and total health care costs can be reduced. However,
precision and accuracy are often problematic in a number of
test formats, and small changes in trends cannot be detected.
There is continuing demand for high-performance clinical
tests, and central laboratories still process the majority of di-
agnostic tests owing to lower unit costs [39, 44].
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